We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sarepta's shares soared Tuesday morning as it presented preliminary phase 1/2 data for potentially curative gene therapy for boys with Duchenne muscular dystrophy (DMD).